Related Experiment Videos
Abstract:
Whether long-term glycemic control will prevent the chronic vascular complications of diabetes mellitus remains unknown. Microangiopathy and accelerated macroangiopathy are prevalent in both type I, or insulin-dependent diabetes mellitus, and type II, or non-insulin-dependent diabetes mellitus. Microangiopathy is predominantly responsible for the excessive morbidity and mortality in type I diabetic patients, whereas accelerated macroangiopathy directly relates to the excessive morbidity and mortality in type II diabetic patients. Institution of euglycemia for short periods will reverse preclinical, functional, renal, and retinal abnormalities, but will not reverse clinical nephropathy and retinopathy. Intensive insulin therapy, although it increases the risk of hypoglycemic encephalopathy, seems rational for type I diabetic patients without vascular complications who can recognize and respond normally to hypoglycemia. In patients with type II diabetes, sulfonylurea therapy, which is associated with fewer adverse reactions than intensive insulin therapy, may lower the risk of atherosclerosis development by correcting hyperglycemia and associated lipid abnormalities.
Insights
Long-term glycemic control may prevent diabetes complications, but short-term euglycemia only reverses early abnormalities. Intensive insulin therapy is suggested for type I diabetes, while sulfonylureas may benefit type II diabetes.
Area of Science:
- Endocrinology
- Diabetology
- Vascular Medicine
Background:
- Chronic vascular complications are a major concern in both type I (insulin-dependent) and type II (non-insulin-dependent) diabetes mellitus.
- Microangiopathy contributes significantly to morbidity and mortality in type I diabetes, whereas macroangiopathy is more related to outcomes in type II diabetes.
Purpose of the Study:
- To investigate the impact of long-term glycemic control on preventing chronic vascular complications in diabetes mellitus.
- To evaluate the reversibility of diabetic abnormalities with short-term euglycemia.
- To assess the safety and efficacy of different therapeutic approaches for glycemic control in type I and type II diabetes.
Main Methods:
- Review of existing literature on glycemic control and vascular complications in diabetes.
- Analysis of the effects of short-term euglycemia on preclinical and clinical diabetic abnormalities.
- Comparison of intensive insulin therapy for type I diabetes with sulfonylurea therapy for type II diabetes.
Main Results:
- Short-term euglycemia can reverse preclinical, functional, renal, and retinal abnormalities but not established clinical nephropathy and retinopathy.
- Intensive insulin therapy for type I diabetes carries a risk of hypoglycemic encephalopathy.
- Sulfonylurea therapy in type II diabetes may reduce atherosclerosis risk by improving hyperglycemia and lipid profiles with fewer adverse reactions.
Conclusions:
- The efficacy of long-term glycemic control in preventing chronic vascular complications of diabetes remains uncertain.
- Therapeutic strategies should be tailored to diabetes type, considering potential risks and benefits.
- Early intervention with glycemic control may be crucial for preventing the progression of microvascular and macrovascular complications.